150 related articles for article (PubMed ID: 9138662)
21. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
22. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
23. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.
Uemura M; Tamura K; Chung S; Honma S; Okuyama A; Nakamura Y; Nakagawa H
Cancer Sci; 2008 Jan; 99(1):81-6. PubMed ID: 17986282
[TBL] [Abstract][Full Text] [Related]
24. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
25. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
26. Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity.
Söderström TG; Bjelfman C; Brekkan E; Ask B; Egevad L; Norlén BJ; Rane A
J Clin Endocrinol Metab; 2001 Feb; 86(2):855-8. PubMed ID: 11158057
[TBL] [Abstract][Full Text] [Related]
27. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
28. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
29. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1132-40. PubMed ID: 22317880
[TBL] [Abstract][Full Text] [Related]
30. A polymorphism in the CYP17 gene and risk of prostate cancer.
Stanford JL; Noonan EA; Iwasaki L; Kolb S; Chadwick RB; Feng Z; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):243-7. PubMed ID: 11895872
[TBL] [Abstract][Full Text] [Related]
31. TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.
Bharaj B; Scorilas A; Giai M; Diamandis EP
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):387-93. PubMed ID: 10794483
[TBL] [Abstract][Full Text] [Related]
32. Association between hormonal genetic polymorphisms and early-onset prostate cancer.
Forrest MS; Edwards SM; Houlston R; Kote-Jarai Z; Key T; Allen N; Knowles MA; Turner F; Ardern-Jones A; Murkin A; Williams S; Oram R; Bishop DT; Eeles RA;
Prostate Cancer Prostatic Dis; 2005; 8(1):95-102. PubMed ID: 15711606
[TBL] [Abstract][Full Text] [Related]
33. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
[TBL] [Abstract][Full Text] [Related]
34. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.
Setlur SR; Chen CX; Hossain RR; Ha JS; Van Doren VE; Stenzel B; Steiner E; Oldridge D; Kitabayashi N; Banerjee S; Chen JY; Schäfer G; Horninger W; Lee C; Rubin MA; Klocker H; Demichelis F
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):229-39. PubMed ID: 20056642
[TBL] [Abstract][Full Text] [Related]
35. Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.
Margiotti K; Sangiuolo F; De Luca A; Froio F; Pearce CL; Ricci-Barbini V; Micali F; Bonafe M; Franceschi C; Dallapiccola B; Novelli G; Reichardt JK
Dis Markers; 2000; 16(3-4):147-50. PubMed ID: 11381197
[TBL] [Abstract][Full Text] [Related]
36. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
[TBL] [Abstract][Full Text] [Related]
37. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
Choi SY; Kim HJ; Cheong HS; Myung SC
Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
[TBL] [Abstract][Full Text] [Related]
38. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
Giwercman C; Giwercman A; Pedersen HS; Toft G; Lundin K; Bonde JP; Lundberg Giwercman Y
Int J Androl; 2008 Feb; 31(1):25-30. PubMed ID: 17376218
[TBL] [Abstract][Full Text] [Related]
40. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
Li J; Coates RJ; Gwinn M; Khoury MJ
Am J Epidemiol; 2010 Jan; 171(1):1-13. PubMed ID: 19914946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
